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INTRODUCTION 
Breast masses include a wide range of pathologies, that can either 
be benign or malignant lesions. Among all breast masses, fibroadenoma 
is the most commonly diagnosed benign breast mass and Invasive Ductal 
Carcinoma is the most common among the malignant masses [1]. 
Although most breast masses are benign in nature, carcinoma 
breast is the most common malignancy in Indian women as reported by 
Gupta et al [2] in 2016 and is the second leading cause of cancer related 
deaths in women, which has recently overtaken the mortality rates of 
cervical malignancies as stated by The National cancer registry of 
India. 
India is now a country which has the largest estimated number of 
breast cancer deaths worldwide. Breast cancer accounts for 27 % of all 
cancers in women in India, with its incidence rising in the early thirties 
and peaking at ages between 50-64 years. As for other cancers concerned 
in India, late stage presentation is also a common scenario for breast 
cancer [2]. 
The BI-RADS stands for Breast Imaging-Reporting and Data System, 
is being a widely followed risk assessment criteria and quality  
  
assurance tool in mammography, ultrasound (USG) and Magnetic 
Resonance Imaging (MRI) [3]. 
BIRADS 1and 2 lesions are clearly benign lesions. BIRADS 3 and 
4 categories are intermediate lesions. BIRADS 5 and 6 are malignant. 
There are various imaging modalities now available in the breast 
radiology. Currently, Sonoelastography is an advanced sonographic 
technique being used in the assessment of suspicious breast masses in 
complement with the conventional B-mode Ultrasonogram. 
Sonoelastography quantifies elasticity of the tissues by means of pressure 
exerted on them. 
The lesions are quantified according to the colour scale in 
Sonoelastogram. Among various scoring methods, the Tsukuba elasticity 
score is the most known and commonly used scoring systems in 
elastography.[4] 
There is a dramatic progress in the field of breast MRI over the 
past decade. MRI has exceptionally high sensitivity for the detection of 
breast cancer and it can aid in depicting cancers that are entirely occult on 
conventional imaging. 
Gadolinium contrast MRI is used to enhance the vascularity of 
malignant breast lesions. Dynamic MR Mammogram with curve patterns 
is recently being used to assess the exact nature of suspicious breast 
masses.  
Many investigators have detailed either enhancement kinetics of 
the lesion or morphology of the lesion to differentiate benign from 
malignant mass lesions identified on contrast-enhanced MR imaging 
studies. But integration of both kinetic and morphologic data is ultimately 
required to achieve optimal discrimination of pathology. 
Breast biopsy is an invasive procedure aimed at confirming the 
breast lesion detection, remains the gold standard in detection of breast 
pathologies. 
  
ANATOMY OF BREAST 
EMBRYOLOGICAL DEVELOPMENT OF BREAST: 
During 6th week of fetal life, primary mammary ridges (milk lines) 
develops from axilla to medial thigh. In later life, only the mammary 
ridge in the pectoral region develops into breast. During 12th to 16th week, 
development of nipple – areolar complex begins. The breast mound 
increases in size during puberty. Usual location of nipple is at 4th 
intercostal space.  
The breast contains adipose tissue and glandular tissue. Breast 
extends from 2nd to 6th ribs. Normal adult breast has nearly 15 to 20 
segments which are demarcated by mammary ducts, converging in a 
radial fashion at the nipple. The number of mammary segments and 
mammary ducts vary in size. The average diameter of mammary duct is 
2mm, converges into lactiferous sinus of 5 – 8 mm diameter.  
Terminal Ductal lobular unit (TDLU):  
TDLU are the basic functional as well as the basic histological unit 
of breast [5]. The size of usual TDLU ranges from 1to 4 mm. The TDLU 
composed of the extra lobular terminal duct, the intralobular terminal 
duct, the lobule [6].  
 
The pathologies of TDLU are: 
• Ductal Carcinoma In Situ (DCIS) 
• Lobular Carcinoma In Situ (LCIS) 
• Fibroadenoma 
• Fibroadenosis and Apocrine metaplasia of breast 
• Breast cysts 
 
The arterial supply to breast perforating branches of internal 
thoracic artery,  branches of 3rd to 8th intercostal arteries, thoracoacromial 
artery, artery to Serratus anterior and lateral thoracic artery. 
Venous drainage from breast is through axillary vein, internal 
thoracic and posterior intercostal veins. 
Nerve supply to breast is via thoracic intercostals nerves from T3 
– T5 and from supraclavicular nerve. 
The lymphatic drainage of breast is via sappey’s plexus 
(subareolar plexus) into three routes [7]: 
• Axillary or lateral pathway (predominant drainage)  
• Internal mammary pathway  
• Retro mammary pathway  
Axillary nodes include the following group of lymph nodes: 
Anterior (pectoral), Lateral (humeral), Posterior (subscapular), Central 
and Apical (terminal) groups. 
 
 Surgical classification of axillary group of nodes is: 
• Level 1 – inferior to pectoralis minor muscle 
• Level 2 – posterior to pectoralis minor muscle 
• Level 3 – medial to pectoralis minor muscle 
 
REVIEW OF LITERATURE 
INCIDENCE AND RISK FACTORS OF CARCINOMA BREAST: 
An annual incidence of about 1,44,000  new cases of breast cancers 
are reported in India, it has become now the most common female cancer 
among urban population. It is been estimated that 1 in 28 Indian women 
is likely to develop breast cancer during her lifetime. It is seen that 
Indians have a much lower incidence carcinoma breast than that of 
western countries, the incidence is- about one-third in urban areas and 
one-ninth in rural regions of India [8]. 
Breast cancer incidence in Indian women varies from as low as 5 
per 100,000 women per year in rural areas to 30 per 100,000 women per 
year in urban areas as stated by National Cancer Registry Programme, 
ICMR: A consolidated report based on the hospital registries. There is a 
wide lack of population screening in Indians on par with corresponding 
over diagnosis in western population is the contributing factor to this 
varied statistics.  
The etiologies for varying incidence in the breast cancer among 
rural and urban women cannot be completely studied, which are more 
likely attributed to the differences in their reproductive and lifestyle 
factors such as Literacy, Dietary habits, age of menarche and menopause, 
age at first child birth, history of abortion, history of intake of oral 
contraceptives and family history of Breast cancer [9, 10, 11] 
Nulliparous women are at two fold higher risk of breast cancer 
compared to multiparous women [10]. Early menarche less than 12 years) , 
multiple abortions (more than 2 ), less duration of breast feeding, and 
consumption of excess dietary  fat (especially animal fat) more than 30 
g/day are all highly associated with breast cancer[12]. 
Women of young age with breast cancer are associated with larger 
size of the tumor, more number of axillary lymph nodes, high tumour 
grade, low rates of hormone receptor-positive status, earlier and frequent 
loco regional recurrences, and poor overall survival rate[13]. 
Genes associated with increased risk of breast cancer are mainly 
BRCA1 (Breast Cancer gene one) and BRCA2 (BReast CAncer gene 
two). Other genes related to development of carcinoma breast include 
ATM, NBN, CDH1, PTEN, CHEK2, RAD50, RAD51C and TP53.  
Women who have no awareness regarding the usual presenting 
symptoms of breast cancer and women who do lack regular habit of self 
examination of the breast are at increased risk of developing breast 
malignancies.  
Women with previous history of benign breast masses are also at 
high risk of developing malignant masses [14]. 
There exists a huge need of efforts at researching, preserving and 
propagating the factors which are likely to be associated with the 
protection of Indian women from developing carcinoma breast. 
There are vast number of ongoing studies & research works on 
the incidence and risk factors of developing carcinoma breast among 
Indians. 
Among various studies, the down listed three studies are vital ones. 
The first vital study is on assessment of various risk factors of 
carcinoma breast in Indian population is the case – control study 
conducted by Nag et al., that aims at evaluation of differential risk factors 
for triple-negative breast carcinoma (TNBC) compared to Estrogen 
Receptor-positive breast carcinoma[15] 
The second vital study is also a case-control study that is looking 
forward at risk factors such as weight and body size (waist – hip ratio, 
BMI) of the affected Indian women patients with carcinoma breast [2]. 
The third study is a cohort study conducted in the rural region of 
Maharashtra by Dikshit et al, concerning on the conventional and also 
germline risk factors of developing carcinoma breast in a longitudinal 
manner. 
There are many research works and studies on the factors that can 
protect from developing breast carcinoma. The protective factors assessed 
are women who have completed their first full term pregnancy at younger 
age (less than 30 years), female who completed more than 3 full term 
pregnancies. Women with regular breast feeding history had significant 
protection against the development of cancer breast as stated by Lai FM 
et al [16]. 
In the non-lactating young women, the breast parenchyma is 
mainly the fibroglandular tissue, with little or no subcutaneous fat. With 
increase in the age and parity of the women, increased fat deposition in 
both the subcutaneous and retromammary zone occurs. 
IMAGING OF BREAST MASSES: 
The X-Ray mammogram is ever the best screening tool available 
for the detection of breast cancer. Mammography can either be screening 
or diagnostic. It is a least expensive modality.  
Regular mammographic views include Cranio-Caudal view and 
Medio-Lateral Oblique views. Other supplementary views can be tailored 
based on patient needs. 
In general, bilateral breast mammogram is recommended for all 
women beginning at the age of 40 years by the American College of 
Radiology, American Cancer Society, and American College of 
Surgeons. For the women who are with great risk of carcinoma breast 
development (i.e., those with higher than 20-25% lifetime risk), annual 
surveillance with MRI is now being recommended [17]. Several researches 
focus that annual mammograms can aid in early detection of breast 
cancers, so that breast-conservation therapies are possible. 
The overall sensitivity of x-ray mammography in detecting the 
breast cancer is about 85%. However, in women with dense breast, the 
sensitivity of mammography is vastly reduced to 47.8-64.4% [18]. 
With the Digital tomosynthesis mammography, 3D views of the 
breast can be obtained, where multiple images of the breast are acquired 
from different angles and reconstructed into the three-dimensional image 
set.  
The main advantage is that its ability to detect masses in dense 
breasts that are likely to get missed on conventional mammogram 
assessment of breasts masses.  
The other technique called ductography is done in patients 
presenting with the nipple discharge, to characterise the mass within the 
dilated ducts and evaluate the cause of duct ectasis. Prior to cannulation 
of ducts, a subareolar craniocaudal magnification view is obtained to 
assess the presence of any calcifications or opacities in breast 
parenchyma. A gentle periareolar massage with minimal pressure on 
“trigger zone” may produce the nipple discharge. This zone is cannulated 
with a straight tip or right angled tip cannula followed by slow injection 
of iodinated contrast material. Imaging is then performed to assess the 
dilated ducts and better evaluation of intraductal masses such as 
papillomas or carcinomas. 
High frequency linear array transducers and high-resolution 
Ultrasonography with the combination of harmonic imaging and with 
real-time compounding helps in better characterization of the mass lesion 
even in cases with dense breast. USG can aid in localizing small foci of 
breast cancers that are readily missed on routine X- Ray mammography 
screening [19].  
The linear 5 to 12 MHz transducer is the optimal one in assessing 
superficial parts of the body, including breasts, since it provides a better 
lateral resolution. The harmonic imaging augments the resolution of 
sonographic images and also reduces the hindrance from reverberation or 
the near-field artifacts. Real-time compound scanning adds to a better 
tissue contrast resolution.   
B mode Ultrasonography is chosen as the initial imaging 
modality woman younger than 30 years presenting with the palpable 
breast lump.  USG aids in better evaluation of mammographic findings 
such as mass like opacities and any focal asymmetric mammographic 
densities. 
Grid technique is widely adopted for routine breast ultrasound. 
Scanning begins transversely in upper outer quadrant, and then 
sliding from top to bottom inferiorly, the similar sweep is repeated in 
saggital plane. 
 
 
 
 
 
 Other adopted technique for breast USG is radial scanning pattern: 
Starting at 12’o clock position, in the saggital plane, the probe is 
turned around the nipple. The same is done in radial and anti-radial plane
  
Normal breast anatomy in USG is divided into three zones : 
1. Pre mammary zone( skin and fat ) 
2. Mammary zone(fibroglandular tissue) 
3. Retro mammary zone(fat and muscles of chest wall) 
 
 
 
 
 Breast lesions are located in terms of 4 quadrants: upper inner, 
upper outer, lower inner and lower outer. 
 
Description in terms of clock positions can precisely locate the 
breast pathologies. 
   
The US lexicon of Sonomammogram includes six morphologic 
features of the solid breast masses such as  
• Shape of the lesion 
• Orientation of the lesion 
• Margin of the lesion 
• Boundary of the lesion 
• The echo texture of the lesion and 
• Posterior acoustic features of the mass 
Orientation and shape of the lesion: 
Orientation of a breast mass can either be parallel or non parallel to 
the skin surface of the breast.  
Shapes can be round or oval. Round (spherical, circular or 
globular) shape is associated with a relatively high probablity of 
malignancy(60%-100%). 
 Oval (elliptical or egg like) shaped mass is described as “gently 
lobulated” (having  two to three fine undulations) or “macrolobulated”  
(if more than three). 
Margins of the lesion :  
The margins of solid breast masses may either be circumscribed or 
noncircumscribed.  
Well defined mass with a sharp zone of transition from the 
surrounding breast tissue is described to have circumscribed margins.  
Presence of an indistinct zone of demarcation between the mass 
and the surrounding breast tissue is noncircumscribed margins.  
Angular margin is described if a lesion has sharp corners. 
Spiculated margins are described when there are lines radiating from the 
periphery of the mass.  
Angular margins and spiculated margins are highly associated with 
malignancy with their incidence rates of 60% and 86% respectively. 
Lesion boundary:  
Can either be a sharp interface between the mass lesion and the 
surrounding normal breast or a wide echogenic transition zone which lack 
sharp demarcation from the rest of tissue. In most cases, a lesion with a 
sharp interface will be benign and with echogenic wide transition will be 
malignant. 
Internal echotexture:   
The echotexture of a breast lesion is described in reference the 
subcutaneous fat within the breast. The lesion can be hypoechoic, 
isoechoic or hyperechoic compared to the subcutaneous fat. 
Posterior acoustic features:  
Posterior acoustic shadowing is a suspicious finding and may be 
associated with cases of complex sclerosing lesion, invasive carcinoma, 
postoperative scar, lymphoma or macrocalcifications and may even be 
seen in normal patients with dense breast tissue.. 
 In case of doubts in assessment of posterior acoustic enhancement, 
compound imaging settings aid in sorting them better.  
Other associated features to be looked for on Sonomammography are: 
the presence of  
➢ Architectural breast parenchymal distortion 
➢ Dilated ducts 
➢ Vascularity of the lesion 
➢ Overlying skin and nipple changes. 
  
Criteria for benign breast lesions on USG are [20],[21]: 
• Masses with well circumscribed and smooth margins 
• Hyperechoic masses, isoechoic or mildly hypoechoic masses 
• Thin echoic capsule around the mass 
• Oval shaped masses with the maximum diameter in the transverse 
 plane 
• Three or less microlobulations. 
Breast ultrasound criteria for characterisation of malignant lesions 
are: 
• Mass having ill-defined borders 
• Spiculated / angular margins 
• Grossly hypoechoic lesion 
• Taller than broader-the maximum diameter in the longitudinal 
 plane 
• Associated Posterior acoustic shadowing and 
• Microcalcifications  
Doppler USG: 
Malignant breast mass are associated with high vascularity, more 
number of centrally located vessels. Since malignant neoplasms require 
neo - angiogenesis for its further growth and metastasis. Doppler criteria 
such as Resistive Index (RI), Pulsatility Index, and flow velocity can aid 
in distinguishing the benign from malignant lesions. Malignant masses 
mostly have a higher RI than the benign ones. 
USG elastography: 
The use of USG elastography is being increasingly used in 
diagnosis of malignant breast masses, in recent times. The studies 
conducted by Zhi H et al[22] and Itoh et al [23] on USG elastography 
highlights that combined use of B-mode USG with Sonoelastography can 
greatly augment the specificity and positive predictive value in precise 
characterization of the breast masses. Elastography is a novel noninvasive 
technique based on evaluation the stiffness or the elasticity of a lesion.  
Elasticity is the mechanical property enabling a substance to get 
deformed, on subjecting it to an external force and also to resume its 
natural shape or size when the external force is removed.  
Nightingale K. et al study suggested that the deformation of a 
tissue is inversely proportional to the stiffness/elasticity of its substance, 
and response time taken by the tissue to return to its natural condition 
varies as a function of the tissue’s histotype [24]. 
Among all tissues, the adipose tissue has greater chance of being 
deformed. The fibrous tissue takes long time to than adipose or muscle 
tissue to return to its original state after deformation. 
There are two different types of elasographic techniques:  
• Strain elastography   
• Shear wave elastography.  
Strain type of elastography, has two different modalities -   strain 
with manual compression and with acoustic radiation force impulse 
(ARFI). 
In “strain elastography”, on compression of tissue in the region of 
interest, the resultant tissue motion takes place in the direction of 
sonographic beam propagation. The tissues are deformed by applying a 
slight manual longitudinal compression using the transducer. 
The tissue deformation occuring in the longitudinal direction is 
directly proportional to the intensity of the compression applied on it.  
The force applied by the manual compression technique is not 
known to the USG machine and the degree of the tissue deformation is 
measured with the variations in radiofrequency of the sonographic beam 
along the axis of the transducer before and after the compression.  
On conversion of the tissue deformation profile into an elastic 
modulus, the “elastogram” image is obtained [25]. Since it is not possible 
to define the intensity of the force applied on the tissue, it is only possible 
to obtain the deformability ratio of the various tissues and the absolute 
tissue elasticity is not derived. The elastography with compression 
technique gives only the qualitative information is obtained and not the 
quantitative data. 
ARFI is done in two different ways. One is a qualitative method, 
similar to strain elastography, which utilises a high intensity short 
acoustic impulse and deform the tissues to create a static elastogram map 
of the tissue’s relative stiffness.  
Another technique is quantitative type, similar to shear wave 
elastography, in which the primary acoustic impulse is focused in the 
region of interest and it leads to propagation of pressure waves in 
transverse axis, to cause deformation of the tissues.  
The velocity of wave Propagation and attenuation are highly 
dependant on the stiffness of the tissue under deformation and also on its 
viscoelasticity. The waves, in general, travel faster in stiffer tissue 
compared to non stiff tissue. 
Both the qualitative and quantitative ARFI methods decreases the 
interobserver variability but the disadvantage is that it only provides static 
details on the tissue elasticity and not the dynamic data like compression 
elastography.  
With ARFI, a qualitative gray-scale map obtained depicting the 
tissue’s relative stiffness as defined by the ARFI-box with simultaneous 
comparision of the corresponding B mode US image. The lighter areas 
represent more deformable tissues than the dark appearing areas. 
Real-time shear velocity (RSV) is a real-time evaluation of the 
propagation of waves along with the lateral deformability of the tissues.  
The pressure waves are generated from a conventional transducer and the 
tissue motion is captured by a sequence images to produce a specially 
designed beam [26] .   
By measuring the local propagation velocity of the pressure waves, 
the RSV creates a two-dimensional map representing the distribution of 
pressure and the visco-elastic properties of the tissues. The exact scores 
of tissue stiffness are expressed in kiloPascals.  
Kumm et al [27] study combined both the elastography score and 
strain ratio to characterise the breast lesions, to reduce the need for breast 
biopsies. 
Jung Min Chang et al [28] compared the shear wave with strain 
ultrasound elastography in their ability to differentiate the benign and 
malignant breast masses. The AUC for shear wave elastography (0.928) 
was similar as that of strain elastography (0.943). He concluded that the 
diagnostic performance of both shear-wave and strain elastography were 
similar.  
However, the sensitivity and specificity of shear-wave and strain 
elastography were similar to each other. However, the sensitivity and 
specificity of shear-wave and strain elastography varies according to 
histology of the, tumor grade and breast thickness. 
The elastograms were evaluated using the Tsukuba Elasticity 
Scoring, it is a 5-point strain scale. 
Score 1: strain noted in entire hypoechoic lesion (the whole lesion 
is seen as green as that of the surrounding normal breast). 
Score 2: strain is not noticed in part of the hypoechoic lesion (the 
lesion is seen as a mosaic pattern of green and blue). 
Score 3: strain shown only in the periphery of the lesion and not in 
the center (the center of the lesion is seen in blue while the peripheral 
areas are in green). 
Score 4: no strain noted in the entire hypoechoic lesion (the entire 
lesion is seen as blue). 
Score 5: no strain seen either in the hypoechoic lesion or in 
surrounding tissue ( both the lesion and surrounding areas are seen as 
blue). 
 
Dynamic Breast MRI is now the most sensitive tool for early 
diagnosis of breast cancer. Kuhl CK et al. [29] suggested that recent 
innovations in breast MRI clarify both morphology of the lesion and the 
contrast enhancement kinetics.  
In various studies on utility of MR Mammogram conducted by 
Bluemke DA et al, Ikeda DM et al [30,31,32], the sensitivity of MRI breast 
in the detection of breast cancer is as high as 90% and the specificity 
varies from  50% to 70%. Orel SG et al. study [33] on preoperative 
evaluation of breast masses by MRI had a sensitivity rate higher than that 
of both X-Ray mammography and USG. Hata T et al. study [34] shows 
that MRI help in better detection of intraductal spread of breast masses 
compared to conventional USG or mammography.  
A recent study by Bilimoria KY et al. study [35] stated that the 
routine use of MRI in women who were already identified as having 
breast cancer increases the rate of detection of synchronous disease.  
Schnall MD et al [36,37] and few other studies suggested the 
combined use of assessment of the time-signal intensity curve to an 
architectural interpretation model results in higher rate of sensitivity and 
specificity. 
 The interpretation of MRI breast is by analyzing: 
• Morphology of  the lesion  
• T1 and T2- intensities of the lesion  
• Kinetics of contrast enhancement by various curve patterns 
Enhancing breast lesions are classified into three major categories: 
focus/foci, masses, and lesion with non-mass enhancement [38]. 
• Focus or Foci (if multiple) is an enhancing area that is less than 
 5mm in its diameter. 
• A mass is a three-dimensional space occupying lesion in the breast.  
• Non-mass like enhancement is region of enhancement without 
any detectable three-dimensional mass lesion.  
Study by Malich Aet al [39] on differentiation of benign and 
malignant breast masses with MR Mammogram suggests the following 
factors of interpretation: 
Shape of the lesion: 
The mass may be round, oval, lobulated with undulating contours 
or irregular in shape. The irregularly shaped masses have 32% chance of 
malignancy. 
Margin of the lesion: 
Margin can be categorised as smooth, spiculated or irregular.  
Spiculated margins are frequently associated with malignant breast 
lesions (80% chance of malignancy). 
  
T1- and T2- features of the lesion: 
High signal on T1 images 
The common lesions are intramammary lymph nodes with fatty 
hilum, fat necrosis and hamartomas.  
The pre-contrast T1 & non fat suppressed sequence depicts the 
presence of fat in a lesion. 
High signal on T2-fat suppressed images 
Lesions appearing hyperintense on T2 images are cystic lesions, 
lymph nodes and fat necrosis. Most T2 hyperintense lesions are benign. 
Only malignant T2 hyperintense lesion is colloid carcinoma. 
Moderate signal on T2-fat suppressed images are invasive 
lobular carcinoma, ductal carcinoma in situ and fibrocystic breast disease. 
Low signal on T2-fat suppressed images are invasive ductal 
carcinoma, scars and sclerotic fibroadenomas. 
Focal perilesional Edema: 
A focal region of T2-hyperintense signal around the lesionis highly 
suspicious of malignancy.  
The hyperintensity increase may be related to presence of increased 
capillary permeability by the tumour related angiogenesis growth factors. 
Architectural Distortion: 
A nonenhanced architectural distortion usually represents radial 
scar; and enhanced architectural distortion usually represents invasive 
cancer. Desmoplastic tethering (hook sign), which is highly suggestive of 
a malignant breast mass is due to invasion of the Cooper ligaments along 
the pectoral muscle direction.  
Skin Thickening and Edema: 
Skin thickening and edema associated with breast mass (untreated) 
are signs of malignancy, mostly of inflammatory carcinoma. In the 
treated breast cases, these occur frequently following radiation therapy. 
Lymph Nodes: 
The mere absence of lymphadenopathy does not differentiate 
benign from malignant masses. Presences of nodes with more than 1 cm 
diameter are seen in malignant masses.  
A lymph node with loss of fatty hilum is seen in malignancy. 
Breast mass enhancement patterns on MRI: 
➢ Homogenous enhancement is presence of uniform and more 
confluent enhancement in the entire mass. 
➢ Heterogeneous enhancement is when there is non uniform 
enhancement; the enhancement varies with mass lesion. 
➢ Rim enhancement is enhancement concentrated in the periphery of 
the mass, has 40% chance of being malignant. It is commonly a 
feature of high-grade invasive Ductal cancer, fat necrosis, and also 
in few inflammatory cysts. 
➢ Enhancing internal septations are the common feature of 
malignancy. 
➢ Central enhancement is the enhancement of the nidus within a 
mass. Usually associated with high-grade Ductal carcinomas. 
The Kinetic curve analysis: 
The initial upslope of the curve in first one to two minutes, can be 
slow, medium or rapid upslope. 
The delayed portion is more than two minutes after the injection of 
contrast can be persistent increase , plateau or washout. 
Type 1 curve: 
Has a slow rise in initial phase with a persistent rise with time. 
A lesion having type 1 curve has 6% chance of malignancy   
Type 2 curve: 
May have either a slow or rapid rise in the initial phase followed by 
a plateau in delayed phase, which has a variance of 10% up or down. 
A lesion with type 2 curve has 29-77% chances of malignancy. 
Type 3 cure: 
The type 3 curve has a rapid rise in initial phase, followed by a 
rapid washout in the delayed phases. 
 A lesion with type 3 curve has high (29-77%) chances of 
malignancy. 
 
Non-mass like enhancement: 
➢ Focal enhancement is when the non-mass enhancement occurs in 
less than 25% of a quadrant in the breast. 
➢ Ductal involvement shows enhancement along a ductal distribution 
and has a 60% chance of malignancy. 
➢ Linear enhancement has enhancement similar to ductal type of 
enhancement, but has no ductal orientation. There is 31% chance of 
malignancy. 
➢ Segmental enhancement refers to enhancement along multiple 
ducts and is associated with 78% chance of malignancy 
➢ Regional enhancement is neither ductal nor segmental but larger 
than focal enhancement and is associated with 21% chance of 
malignancy 
➢ Diffuse non-mass enhancement occurs typically in benign masses. 
Internal Enhancement Pattern in Non-mass like enhancement 
The punctuate enhancement occurs mostly in benign lesions and is 
associated with 25% chance of malignancy.  
Clumped enhancement is another important non-mass enhancing 
pattern, and is associated with 60% chance of malignancy. 
Heinig et al, study stated the USG characterisation of breast 
lesions using BIRADS-US criteria [40]. 
BIRADS: 
BIRADS classification is devised by American College of 
Radiology, last updated in November 2015, and is the widely used 
classification system for breast masses. 
The latest version classifies the breast lesions into six broad 
categories: 
• BIRADS 0: 
o Incomplete imaging, further imaging or information is required, 
such as compression, magnification or other special 
mammographic views. 
o When the previous image not available at the time of examination. 
o Once the additional imaging studies are completed, a final 
assessment is done. 
• BIRADS 1: negative mammogram, symmetrical breast tissue and 
no detectable masses, no architectural distortions or no suspicious 
calcifications seen. 
• BIRADS II: benign finding such as  
o Fat-containing lesions such as: oil cysts, breast lipomas, 
fibroadenolipoma or mixed density hamartomas and galactoceles 
o Simple breast cysts 
o Follow up after breast conservative surgery 
o Calcified or Involuting fibroadenomas 
o Intramammary lymph nodes 
o Vascular calcification  
o Breast Implants 
In BIRADS II lesions, a routine screening mammogram is 
suggested. No invasive procedure needed as the chance of malignancy is 
0% 
• BIRADS III: probably benign, short interval follow-up (6 months) 
or continuous surveillance is suggested. Likelihood of malignancy 
is more than 0% and less than 2%. This includes 
o Nonpalpable, circumscribed mass on a routine mammogram 
(unless it can be shown to be a simple cystic lesion, an 
intramammary lymph node, or any another benign finding). 
o Focal asymmetry which becomes less dense on spot compression 
view  
o Solitary group of punctuate calcifications 
The initial short term follow-up of a BIRADS III lesion is an 
unilateral mammogram at 6 months, then a bilateral follow-up of 
examination is suggested at 12 months interval. Assuming stability 
perform a follow-up after one year and optionally after another year. 
If the finding shows no change in the follow-up, the final assessment is 
changed to BIRADS II (benign) and no further follow up is needed. 
 
 
• BIRADS IV: suspicious abnormality requires biopsy.  
o There is a mammographic appearance which is suspicious for 
malignancy 
o These can be further divided as  
• BIRADS IVa: low level of suspicion for malignancy   
• BIRADS IVb: intermediate suspicion for malignancy 
• BIRADS IVc: moderate suspicion for malignancy 
• BIRADS V: there is a mammographic appearance which is highly 
suggestive of malignancy, biopsy should be taken 
• BIRADS VI: a biopsy/ histopathology proven malignancy 
PATHOLOGY AND PROGNOSIS OF MALIGNANT BREAST 
MASSES: 
Breast carcinomas generally arise from the terminal duct lobular 
unit (TDLU). Breast cancers are broadly divided into two groups: the 
carcinomas and the sarcomas.  
Carcinomas contribute to the vast majority of all breast cancers; 
they arise from the epithelial cells in the breast.  
Sarcomas are rare masses that arise from the stromal (connective 
tissue) cells of the breast.  
In situ (preinvasive) carcinoma is when the lesion not yet invaded 
the surrounding breast tissue. Masses that originates from the ducts are 
known as ductal carcinomas, while those from the lobules are known as 
lobular carcinomas. 
Ductal carcinoma in situ (DCIS) is subdivided to comedo, solid, 
cribriform, papillary and micropapillary histological types. It takes many 
years for the transformation of pure DCIS to an invasive ductal mass [41]. 
Lobular carcinoma in situ (LCIS), show lack of E-cadherin and 
Beta catenin expression in the tumour cells and also associated with 
presence of high molecular weight (HMW) keratin [42]. Invasive 
carcinoma develops in about 25%-35% cases (at a rate of 1% per year) 
who are observed for more than a period of 20 years. 
Approximately 80% of breast carcinomas are mainly invasive 
ductal carcinoma, followed by 10-15% of cases with invasive lobular 
carcinomas. 
Invasive lobular carcinoma (ILC) usually occurs in 
postmenopausal women and may be related to hormone replacement 
therapy [41].  
Inflammatory Breast Cancer (IBC)- is a rare type of breast 
carcinoma that is associated with reddening and inflammation of the skin 
of the affected breast. Most IBC are invasive ductal carcinomas. 
Paget ’s disease Of Nipple- an uncommon pathology of breast 
carcinoma that is associated with red and scaly rash on the skin surface of 
the breast.  
Phyllodes tumour of the breast or cystosarcoma phyllodes, is an 
uncommon type in which the tumour cells that grow quickly in a leaf-like 
pattern.  
The prognostic factors suggested by College of American 
Pathologist: 
• The axillary lymph node status is the most consistent prognostic 
factor among all. 
• The five year survival for patients with node-negative breast cancer 
is 82.8% and it is 73% for 1-3 positive nodes, 45.7% for 4-12 
positive nodes and it is 28.4% for >13 positive nodes[43] 
• Invasive ductal ductal carcinoma and inflammatory breast cancer 
have high propensity for axillary nodal metastases. 
• Size of the tumour - Patients with tumour <1 cm had a 5-year 
survival rate of 99% as compared with 89% survival for tumours 
between 1cm and 3cm and 86% survival for tumours between 3cm 
and 5cm[44].  
• The presence of lymphatic/vascular invasion  
• Age of the patient influences the prognosis – worse prognosis is in 
patients younger than 35 years of age. 
• Histologic grading by Scarff-Bloom-Richardson (SBR) 
classification is widely followed - it includes miotic index, 
pleomorphism and differentiation of the cells and is scored from 1 
to 3.  
• Histologic subtypes – commonly tubular, mucinous and medullary 
subtypes have a better prognosis than unspecified breast cancer [45]. 
• Response to neoadjuvant therapy. 
• ER/PR (Estrogen and Progesterone receptors) status  
MANAGEMENT OF CARCINOMA BREAST: 
Histopathology is the gold standard confirmatory tool in breast 
masses.  
Fine Needle aspiration biopsy (FNAC): 
The sample of cells or fluid aspirated from an easily accessible 
lump is smeared on a glass slide and sent to pathology. Image guidance 
such as ultrasound, MRI or mammography is often sought in deep masses 
not detected on palpation.  
This procedure is less invasive, least expensive and it is less time 
consuming. The limitation is pathologist often cannot tell if the sample 
from the tumour is carcinoma in situ or invasive breast cancer. 
Core-Needle Biopsy: 
A wide bored hollow needle is used to take out several small core 
of tissue (about 1/16 to 1/8 inch in diameter and about ½-inch long) via 
biopsy gun.  
Vacuum-assisted breast biopsy (VABB): 
With vacuum assistance, required sample can be obtained via a 
single insertion. The advantage of complete lesion removal with VABB  
are to eliminate the sampling error, to reduce the likelihood of a 
histological underestimation, to decrease the rate of re-biopsy.  
Open (surgical) biopsy: 
There are two types: 
The excisional surgical biopsy – complete removal of the lesion 
concern along with the surrounding margin of normal breast tissue. 
In incisional surgical biopsy – only a part of the breast lesion is 
removed. This biopsy is usually done on large lesions.  
With “needle” or “wire” localization, a thin wire is inserted via the 
center of the hollow needle to precisely localize the exact area of biopsy. 
The hook at the wire end prevents it from slipping out of the soft breast 
tissue.       
The radiologist then will remove the hollow needle, and only the 
wire will be left as a guide to localize the breast mass.  
Surgery: 
Based on the type and the stage of the breast tumour with the aim 
of complete excision of the mass with clear margins, Surgery can be 
lumpectomy (removal of the mass alone), quadrantectomy (one- fourth of 
breast is excised) or mastectomy (removal of entire breast tissue). 
Sentinel lymph node resection is been increasingly practised along with 
breast surgeries. 
Radiotherapy: 
 External beam radiotherapy or brachytherapy is administered to 
the post operative bed in cases of conservative breast surgeries.  
  
Chemotherapy: 
Conventional or liposomal Doxorubicin or Daunorubicin is widely 
used. 
Other drugs include Cyclophosphamide, Flurourcail, Mitoxantone 
and Paclitaxel. 
Hormone therapy: 
Hormone therapy is used as a neoadjuvant or adjuvant treatment 
modality, mainly in cases of hormone receptor positive cases such as ER 
(Estrogen Receptor) PR (Progesterone Receptor) positive.  
Tamoxifen is the widely used drug with anti-estrogenic activity. 
 Toremifene is less commonly used drug with similar activity. Aromatase 
inhibitors such as Letrozole, Anastrazole and Exemastane are other 
alternatives. 
Gene therapy: 
Includes oncogene inactivation that interferes with the activation of 
erbB-2 and activation of tumour suppressor gene such as p53.    
 
 
 
STAGING OF BREAST CANCER 
 
Stage 0 Tis , N0 , M0 * Ductal or Lobular carcinoma in situ (DCIS) ,  
Stage 
IA 
T1 , N0 , M0 The tumor is 2cm and has not spread to 
lymphnodes (N0) or distant sites(M0) 
Stage 
IB 
T0 or T1 , N1 , 
M0 
Tumor is 2cm  with micrometastases  in 1 to 3 
axillary lymph nodes  
Stage 
IIA 
T0 or T1 , N1 
(but not N1) , 
M1 
Tumor is 2cm and either : 
It has spread to 1 to 3 axillary (underarm) 
lymph nodes  with the cancer in lymphnodes  
greater than 2mm across (N1a).  
OR 
Tiny amounts of cancer are found in internal 
mammary lymph nodes (those near the breast 
bone) on sentinel node biopsy (N1b). 
OR 
Cancer has spread to 1 to 3 axillary lymph 
nodes and to internal mammary lymph nodes 
(those near the breast bone) on sentinel node 
biopsy (N1c). 
 
OR 
 
  T2,N0,MO 
Tumor is more than 2cm to 5cm  
Stage 
IIB 
T2,N1,MO 
Tumor is more than 2cm to 5 cm but not more 
than 5cm across. It has spread to 1 to 3 axillary 
lymph nodes and/or tiny amounts of cancer are 
found in internal mammary lymph nodes on 
sentinel node biopsy (N1). 
OR 
  T3,N0,MO 
Tumor is larger than 5cm across in size but 
does not grow into the chest wall or skin (T3).  
Stage 
IIIA 
T0 to 
T2,N2,MO 
The tumor is not more than 5cm. It has spread 
to 4 to 9 axillary lymphnodes, or it has enlarged 
the internal mammary lymph nodes (N2). 
OR 
  
T3,N1 or 
N2,MO 
Tumor is larger than 5cm it has spread to 1 to 9 
axillary lymphnodes, or to internal mammary 
lymph nodes (N1 or N2).  
Stage 
IIIB 
T4 , N0 to N2 , 
M0 
Tumor of any size growing into the chest wall 
or skin (T4): 
# It has not spread to lymph nodes. 
# It has spread to 1 to 3 axillary lymph nodes 
and/or tiny amounts of cancer are found in 
internal mammary lymph nodes on sentinel 
node biopsy (N1). 
# It has spread to 4 to 9 axillary lymphnodes, or 
it has enlarged the internal mammary lymph 
nodes (N2). 
The cancer hasn't spread to distant sites (M0). 
Inflammatory breast cancer is classified as T4 
and is atleast IIIB.If it has spread to many 
nearby lymphnodes (N3) it could be stage IIIC 
and if it has spread to distant lymphnodes or 
organs (M1) be stage IV. 
Stage 
IIIC 
any T , N3 , M0 
The tumor ia any size ( or cant be found) , and 
one of the following applies: 
# Cancer has spread to 10 or more axillary 
lymph nodes (N3). 
# Cancer has spread to infraclavicular lyph 
nodes (N3). 
# Cancer has spread to supraclavicular lyph 
nodes (N3). 
# Cancer has spread to 4 or more  axillary 
lymph nodes and/or tiny amounts of cancer are 
found in internal mammary lymph nodes on 
sentinel node biopsy (N3). 
The cancer hasn't spread to distant sites (M0). 
Stage 
IV 
any T , any N , 
M1 
The cancer can be any size ( any T )and may or 
may  not have spread to near by lymph nodes 
(any N). It has spread to distant organs or to 
lymph nodes far from the breast (M1). He most 
common sites of spread are the bones , liver , 
brain or lungs. 
 
 
 
 
 
 
 
  
 
AIMS AND OBJECTIVES  
• To assess and compare the accuracy of Sonoelastogram breast and 
Dynamic MR Mammogram in predicting benign vs. malignant 
breast masses in BIRADS III & above lesions. 
• To assess the ability of ultrasound elastography and MR 
Mammogram to predict malignant nature of breast masses, with 
subsequent recommendation for biopsy. 
  
MATERIALS AND METHODS 
STUDY METHODOLOGY: 
STUDY DESIGN: 
Prospective cohort study         
STUDY PERIOD: 
From August 2016 – May 2017, for a period of 10 months 
STUDY POPULATION:  
Female and male patients, who present with breast masses, of age 
group 25 years and above.  
Study population is chosen from the patients who attend Out 
Patient Department in Government Kilpauk Medical College and 
Hospital, Chennai. 
INCLUSION CRITERIA: 
• Case presenting with breast masses of age 20 years and above 
• Cases with BIRADS III and above categories ( on assessment with 
digital ammogram and conventional B mode Ultrasonogram) 
• Breast masses more than 5 mm in size ( elastogram can be fruitful 
only in lesions more than 5 mm) 
• Cases who have undergone imaging with both sonoelastogram and 
MR Mammogram 
• Cases with histopathological proof  
EXCLUSION CRITERIA: 
• Lesions that were BIRADS I & II on initial assessment 
• Lesions in postoperative breast ( the fibrous changes in post 
operative breast provides a false positive high score on elastogram) 
• Cases who are non complaint for MRI (claustrophobia, patients 
with metallic implants such as cochlear implants, pacemakers, 
defibrillators or with metallic catheters) 
• Cases with allergy to Gadolinium contrast 
• Cases with elevated renal parameters, that prevent the use of 
Gadolinium contrast medium 
DATA COLLECTION: 
Data collection was performed in the included study group using a 
standard questionnaire/ proforma. 
Proforma includes the basic patient details such as name, age, sex, 
address, education status, occupation, dietary habits and history of 
smoking/ alcohol.  
General examination of the patient, local examination of the breast 
mass by inspection and palpation was also assessed and recorded in the 
proforma. 
METHODOLOGY: 
The study was begun after obtaining institutional ethical committee 
clearance. All the included cases were subjected to imaging after 
obtaining written consent. 
After basic clinical examination and local palpation of the breast 
mass, Real-time conventional B-mode Ultrasonography examination 
were performed in a GE Health care Logiq S7 scanner, with a wide band 
linear array probe of 7.5 MHz frequency (5 – 13 MHz), with a foot print 
of 12.7 x 47.1 mm.  
Sonographic assessment of location of the lesion in terms of: 
• Quadrant of the breast (upper outer, upper inner, lower outer and 
lower inner) 
•  Zone in which the lesion was located  
•  Clock’s position 
Other sonographic features described were: 
 Echotexture of the lesions were defined as  hypoechoic or 
isoechoic or hyperechoic (compared with the subcutaneous fat)  
 Margins of the lesion – well defined, ill defined, spiculated, 
lobulated 
 Presence of axillary nodes 
 Categorised BIRADS of the lesion with sonogram  
Total of 166 cases with breast masses were sent from Out Patient 
Department. Among them, conventional B mode Ultrasonogram was 
performed in all cases. They were categorized according to BIRADS 
classification.  
BIRADS I and II were excluded. 63 cases with BIRADS III and 
above were chosen for the study. Sonoelastogram was performed in all 63 
cases.  MRI Mammogram with dynamic contrast was performed only in 
51 cases. HPE (Histo Pathological Examination) was done only in 45 
cases. 
The included sample size in this study is 45 cases (44 female and 1 
male). 
All 45 cases were subjected to sonoelastogram and MR 
Mammogram within a maximum period of 7 days interval and HPE proof 
was obtained in all cases within 15 days from their initial imaging 
diagnosis. 
Histopathology was confirmed with open breast biopsy in 26 cases, 
core needle biopsy was done in 11 cases and FNAC in 8 cases. Among all 
open breast biopsies, Needle localization assisted surgical biopsy 
performed in 2 cases. 
With the patient in supine position, after obtaining clinical history 
and initial local examination, Conventional B mode USG breast was done 
by grid technique either in radial plane.  
Only lesions with BIRADS III & above are chosen for the study. 
After localization of the lesion, sonoelastogram was performed 
immediately in the same sitting. Strain wave elastogram was performed 
with the same linear array transducer. The elastography parameters were 
set uniform for all cases as color gain at 26%, high frame rate and density 
at 2. 
The probe was placed perpendicular to the breast and parallel to 
long axis of the mass lesion. Care was taken to avoid lateral angulation of 
the probe.  
The elastography box was chosen large enough to the cover the 
lesion. Usually the cephalic end of the box is placed under the skin, 
including the subcutaneous tissue and the caudal end of the box is placed 
to include the underlying pectoralis major muscle; lateral borders were 
usually set more than 5 mm from the lesion’s boundary. 
The lesion should be within the center of the box. Then, few 
consecutive compressions- decompressions were manually applied with 
the probe on the breast and the adequacy of the compression is assessed 
by the vibration scale in the left corner of the image. A minimum of 3 to 
5 acquisitions are obtained per lesion. 
During this compression, the grey scale images of the mass lesion 
were simultaneously seen in the screen and can be used to precisely 
localize the mass. 
Tsukuba elasticity scoring was applied to all lesions depending on 
the basis of visual color coding. Scores from 1 to 5 were assigned based 
on its interpretation. 
In all cases with suspicious masses, MRI Mammogram was 
performed in 1.5T GE MRI with the use of dedicated breast coil. Before 
MR imaging, intravenous access was obtained preferably in antecubital 
vein for contrast administration. 
MRI breast is usually scheduled from 7th to 12th day of  the 
menstrual cycle. This is the optimal phase to avoid misinterpretation from 
normally enhancing breast parenchyma due to hormonal effects.  
Patients were well explained about the procedure and are advised 
to remove metallic pins, jewellery, hearing aids and other metal objects 
outside the MRI gantry. 
Dedicated breast coils were used. Patients were positioned 
comfortably in prone position, placing both the breasts into the cups of 
the breast coil and a cushion is kept under the head. Adequate 
compression was applied to the breasts with centering at the level of 
nipple.  
The preferable phase encoding directions is from right to left for 
axial sections and from superior to inferior for saggital sections inorder to 
avoid the motion artifacts.  
The following sequences are usual protocol adopted in our 
institution for MR Mammogram . Axial and sagittal T1, axial and sagittal 
T2, axial STIR, DWI, fat saturation images and post contrast T1 dynamic 
imaging successively for 6 times are obtained.  
After obtaining the plain study, intravenous contrast of gadolinium 
at a dose of 0.1 mmol/kg at a rate of 2ml/sec was administered. It was 
followed by saline infusion of about 20ml.  Subtraction images were 
obtained by post processing of the contrast enhanced images(pre contrast 
raw data set is subtracted  from each set of post contrast images). These 
subtraction images are crucial for exact analysis of contrast enhancement 
of the lesion. Time intensity curves were obtained with a specific “ 
functool ” application.  
Parameters set for T1 were: 
TR (repetition time): 400 – 620 ms 
TE (echo time): 10 – 30 ms 
Flip angle: 90 degrees 
Parameters set for T2 were: 
TR: 2000 – 4000 ms 
TE: 80 – 120 ms 
Flip angle: 90 degrees 
Slice thickness: less than 3 mm 
Interval gap: 0.5 
FOV: 320 x 320 mm 
Matrix: 256 x 192 
Pixel: less than 1 mm in each plane for dynamic post contrast 
images to reduce the effect of volume averaging 
To generate the time intensity curves, ROI was placed on the most 
enhancing part of the lesion. The size of ROI should preferably be more 
than 3 pixels. 
The curves were described as type I to III. Type I curve is when 
there is progressive increase in signal intensity on successive images. 
Type II curve pattern is when there is initial increase in signal intensity, 
followed by a plateau (flattening). Type III curve is interpreted if there is 
initial increase in signal intensity, followed by rapid decrease in signal 
(washout).  
  
 CASE - 1 
32 years old female presented with hard lump in right breast. 
B mode Ultrasound shows a well defined hypoechoic lesion of 2.2 
x 1.5 cm with irregular margins. It was categorized as BIRADS IV. 
 
 
 
USG Elastogram shows type 5 score as strain seen in entire lesion 
and also in its periphery. 
 
 
 
  
 
MR Mammogram shows ill defined T1 hypointense lesion and 
STIR hyperintense lesion in upper outer quadrant of right breast. 
 
 
  
 
Mass lesions in right breast shows intense enhancement in early 
phase with rapid washout of contrast – suggestive of type 3 curve. 
On histopathology, this lesion turned out to be a case of invasive 
ductal carcinoma. 
 
 
CASE 2 
32 years old young female presented with left breast pain on and 
off for 2 months and diffuse swelling was noted in left breast on clinical 
examination.  
B mode USG shows ill defined heteroechoic lesion, predominantly 
hyperechoic in upper outer quadrant of left breast, suggestive of BIRADS 
III. 
 
 
On Elastography, the lesion is seen as a mosaic pattern of green 
and blue, suggestive of score 2. 
 
 
 
 MR Mammogram shows ill defined T1 hypointense lesion and T2 
hyperintense lesion in upper outer quadrant of left breast 
]
 
  
On contrast, non mass like enhancement noted with type 1 curve 
pattern on kinetic curve analysis. 
 
Histopathology – exuberant proliferation of  lymphocytes and 
histiocytes with granulomatous response and focal areas of necrosis in a 
background of neutophilic infiltrate suggestive of Granulomatous 
mastitis. 
 
Chronic granulomatous mastitis is mimicker of malignancy, has to 
be ruled out carefully. 
  
CASE 3 
44 years female with large lump in right breast. On USG , large 
well defined hypoechoic mass lesion with smooth margins measuring 7.0 
x 7.2 cm. 
 
 
 
On USG Elastogram, score3 pattern (majority of lesion in blue 
with areas of green and red mixed within) noted. 
 
 
 
  
 
MRI T2 & T1 axial images shows a large well defined T2 mixed 
intense and T1 hypointense mass lesion in right breast with minimally 
lobulated margins. No evidence of axillary adenopathy. 
 
 
  
 
Dynamic contrast MRI shows upslope in initial phase with 
progressive contrast enhancement in delayed phase – suggestive of a type 
I curve.  
Final histology turned out to be fibroadenoma (giant in size).  
 
 
 
 
 
 
  
CASE 4 
21 years old male presented with painless lump beneath the left 
nipple. 
B mode USG shows heteroechoic mass lesion in the retro areolar 
region, measuring 2.6 x 2.0 cm with irregular margins suggestive of 
BIRADS IV. 
 
USG elastogram shows predominantly blue colour within the entire 
hypoechoic lesion suggestive of score 4. 
 
 
 
 
  
 
MRI axial and sagittal STIR images show well defined 
hyperintense mass lesion with irregular margins in left retroareolar region 
measuring  2.0 x 2.2 cm. Normal right breast and no abnormal axillary 
nodes. 
 
  
Dynamic contrast MRI shows progressive contrast enhancement in 
initial phase and in delayed phase with a type I curve.  
 
On histopathology, the lesion turned out to be a case of nodular 
gynecomastia. 
 
 
 
CASE 5 
58 years old female presented with bloody discharge from the left 
nipple. 
B mode USG shows, dilated duct with few calcifications in retro 
mammary region. 
 
 
USG Elastogram shows type 3 score as strain seen only in the 
periphery of the lesion 
  
MR mammogram shows focally dilated duct along the nipple line. 
Dynamic contrast MRI shows progressive contrast enhancement in 
initial phase with plateau in delayed phase with a type II curve.  
HPE shows unicentric clonal proliferation of ductal cells with 
mitotic nuclei without invading the surrounding stroma suggestive of 
DCIS – Ductal Carcinoma In Situ. 
CASE 6 
22 years female presented with bilateral breast lumps. 
B mode USG shows multiple well defined hypoechoic lesions of 
varying sizes with lobulated margins in both breasts. 
 
This is the largest lesion in right breast with lobulated margins – 
suggestive of BIRADS III. 
  
USG Elastogram shows lesion with score 2 strain (mosaic 
attenuation) pattern in this hypoechoic lesion. 
Few other lesions in both breasts had Elastographic score 2 and 3. 
 MR T2WI shows well defined hyperintense mass lesions in both 
breasts with lobular margins in many and irregular margins in few 
lesions. 
 
Mass lesions in both breasts shows intense enhancement in early 
phase with rapid washout of contrast – suggestive of type 3 curve. 
 
 
 
  
 
   
 
 
 
 
On histopathological analysis, both breasts show multiple 
fibroadenomas in inflammatory background. 
  
STATISTICAL ANALYSIS AND RESULTS 
The Data was entered in a excel worksheet and double 
checked.IBM SPSS version 22 software is used for statistical analysis.  
Descriptive analysis:  
Descriptive analysis was carried out using mean and standard 
deviation for quantitative variables.  
The frequency and proportion are used for categorical variables.  
Data was also represented using appropriate diagrams like bar 
diagram, pie diagram and box plots. 
The sensitivity, specificity, positive and negative predictive values 
and diagnostic accuracy of the Sonoelastography and Dynamic MR 
mammogram against gold standard – the Histo Pathological Examination 
(HPE) along with their 95% CI (Confidence Interval) are computed and 
presented.  
Reliability of the screening test is assessed by kappa statistics 
along with its 95% CI and P Value. 
P value < 0.05 is considered statistically significant. 
 
 
 Table 1: Descriptive analysis for Age in study population (N= 45) 
 
Parameter 
Mean 
±STD 
Median Min Max 
95% C.I. for EXP(B) 
Lower Upper 
Age 
39.71 
± 
11.88 
37.00 21.00 74.00 36.14 43.28 
 
Table 2: Descriptive analysis of Age Group in study population 
(N=45) 
 
Age Group Frequency Percentages 
Up to 29 9 20.00% 
30-39 14 31.11% 
40-49 12 26.67% 
50-59 8 17.78% 
60 and above 2 4.44% 
 
 
 Table 3: Descriptive analysis of Gender in study population (N=45) 
Gender Frequency Percentage 
Female 44 97.78% 
Male 1 2.22% 
 
Fig 1: Bar chart of Age Group distribution in study population 
(N=45)
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 Fig 2: Bar chart of Gender distribution in study population 
 
Table 4: Descriptive analysis of Right/Left in study population 
(N=45) 
Right/Left Frequency Percentages 
LEFT 20 44.44% 
RIGHT 19 42.22% 
BOTH 6 13.33% 
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 Fig 3: Pie chart of Right/Left distribution in study population (N=45) 
 
 
Table 5: Descriptive analysis of MRI curve in study population 
(N=45) 
MRI curve Frequency Percentages 
TYPE I 18 40.00% 
TYPE II 9 20.00% 
TYPE III 18 40.00% 
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 Fig 4: Pie chart of MRI curve distribution in study population (N=45) 
 
 
Table 6: Descriptive analysis of Sonoelastography Grade in study 
population (N=45) 
Sonoelastography Frequency Percentage 
Grade-2 12 26.67% 
Grade-3 18 40.00% 
Grade-4 12 26.67% 
Grade-5 3 6.67% 
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 Fig 5: Pie chart of Sonoelastography Grade distribution in study 
population (N=45) 
 
 
Table 7: Descriptive analysis of BIRADS in study population (N=45) 
BIRADS Frequency Percentage 
III 22 48.89% 
IV 16 35.56% 
V 6 13.33% 
VI 1 2.22% 
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 Fig 6: Pie chart of BIRADS distribution in study population (N=45) 
 
 
Table 8: Descriptive analysis of Final Histopathological Diagnosis 
(HPE) in study population (N=45) 
Final Diagnosis(HPE) Frequency Percentage 
Malignant 19 42.22% 
Benign 26 57.78% 
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Fig 7: Bar chart of Final Histopathological Diagnosis (HPE) 
distribution in study population (N=45) 
 
Table 9: Association of Final  Histopathological Diagnosis (HPE) 
with dynamic MRI mammogram curve category of study population 
(N= 45) 
MRI Curve 
category 
Final Histopathological 
Diagnosis(HPE) 
Chi 
square 
P-value 
Malignant Benign 
Malignant 17 (89.47%) 1 (3.85%) 
33.537a <0.001 
Benign 2 (10.53%) 25 (96.15%) 
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Table 10: Predictive validity of dynamic MRI mammogram curve 
category as compared Final Histopathological Diagnosis (HPE) 
(N=45) 
Parameter Value 
95% CI 
Lower Upper 
Sensitivity 89.5% 75.67% 100.0% 
Specificity 96.2% 88.76% 100.0% 
False positive rate 3.8% 1.00 % 11.2% 
False negative rate 10.5% 1.00 % 24.3% 
Positive predictive value 94.4% 83.86% 100.0% 
Negative predictive value 92.6% 82.71% 100.0% 
Diagnostic accuracy 93.3% 86.05% 100.0% 
 
Reliability: (Kappa statistic) 
 Kappa statistics Std. Error P-value 
Measures of 
Agreement 
0.862 0.077 <0.001 
 
Positive likelihood ratio: -6.7 
Negative likelihood ratio: 0.07 
Table 11: Association of Final Histopathological Diagnosis (HPE) 
with sonoelastography Grade category of study population (N=45) 
 
Sonoelastography 
Grade category 
Final Histopathological 
Diagnosis(HPE) Chi 
square 
P-
value 
Malignant Benign 
Malignant 13 (68.42%) 2 (7.69%) 
18.219a <0.001 
Benign 6 (31.58%) 24 (92.31%) 
 
Table 12: Predictive validity of Sonoelastography Grade category as 
compared Final Histopathological Diagnosis (HPE) (N=45) 
Parameter Value 
95% CI 
Lower Upper 
Sensitivity 68.4% 47.52% 89.3% 
Specificity 92.3% 82.06% 100.0% 
False positive rate 7.7% 1.00 % 17.9% 
False negative rate 31.6% 10.68% 52.5% 
Positive predictive value 86.7% 69.46% 100.0% 
Negative predictive value 80.0% 65.69% 94.3% 
Diagnostic accuracy 82.2% 71.05% 93.4% 
 
Reliability: (Kappa statistic)  
 Kappa statistics Std. Error P-value 
Measures of Agreement 0.625 0.118 <0.001 
 
Positive likelihood ratio: -23.9 
Negative likelihood ratio: 0.26 
 
Fig 8: Bar chart of HPE distribution in study population (N=45) 
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Table 13: Descriptive analysis of Histopathological Diagnosis in study 
population (N=45) 
Histopathological Diagnosis Frequency Percent 
Fibroadenoma 13 28.89% 
Dcis- ductal carcinoma in situ 8 17.78% 
Invasive ductal carcinoma 5 11.11% 
Duct ectasia 3 6.67% 
Phylloides 2 4.44% 
Inflamatory carcinoma 2 4.44% 
Granuloma 2 4.44% 
Mastitis 2 4.44% 
Invasive lobular carcinoma 2 4.44% 
Ductal papilloma 1 2.22% 
Fibroadenosis 1 2.22% 
Hemorrhagic cyst 1 2.22% 
Medullary carcinoma 1 2.22% 
Mucinous carcinoma 1 2.22% 
Nodular gynaecomastia 1 2.22% 
 
  
  
Fig 9: Pie chart of HPE distribution in study population (N=45) 
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DISCUSSION 
Our study consists of 45 cases. Among the study group, female 
were 97.88% and only one Male (2.22%) was included. (table 3 & figure 
2). 
The mean age of cases included in our study was 39.71 years with 
a standard deviation of 11.88. The youngest person was 21 years old and 
the oldest person was 74-years-old. (table1). Majority (31.11%) subjects 
belonged to 30 to 39-years age group, followed by 40 to 49-years age 
group (26.67%). (Table 2 & figure 1). 
This age statistics in our study is contemporary with the present 
trend in the incidence of breast cancer among Indian women which is in 
increasing numbers of female from 25 to 40 years of age as stated by 
Sandhu et al [46] and Somdatta et al et al [47] 
Müller-Schimpfle et al [48] studied the correlation between age of 
the patient and contrast enhancement, demonstrated that contrast 
enhancement is better in patients aged 35–50 years than that in younger 
and older patients. Our study did not show any significant association 
between age of the patient and contrast enhancement. 
Among the breast pathologies studied, pathologies are seen in the 
left breast in 44.44%, right breast in 42.22% and bilateral in 13.33%. 
(Table 4 & figure 3). Similar to few previous studies [23,30,31] there is no 
statistical difference between incidence of malignant masses to the side of 
the breast affected. 
Among the Final Diagnosis (HPE) of the studied breast 
pathologies, malignant lesions were noted in 42.22% and Benign lesions 
in 57.78% . (Table 8 & figure 7) 
Fibroadenoma is the most commonly diagnosed benign breast mass 
and Invasive Ductal Carcinoma is the most common among the malignant 
masses as analysed by Schoonjans JM et al [1]. 
Similarly, among various histopathological diagnosis of breast 
masses included in this study, there were 13 cases (28.89%) of 
fibroadenomas, few were giant fibroadenoma and one case was with 
multiple fibroadenomas in inflammatory background which were 
misdiagnosed as malignant by imaging. 
Among the malignant masses, the incidence of DCIS (Ductal 
Carcinoma In Situ) is high. There were 8 cases of DCIS and 5 cases of 
Invasive Ductal Carcinoma.  
The other benign masses found in our study were 3 cases of duct 
ectasia, 2 cases of phylloides tumor, 2 cases of chronic mastitis, 2 cases 
of granulomas, 1 case of intraductal benign papilloma, fibroadenosis and  
haemorrhagic cyst. 
Among other malignant masses, 2 cases of Inflammatory and 
Invasive Lobular carcinoma, 1 case of Medullary and Mucinous 
carcinoma was found. 
Among the Dynamic MRI Mammogram curves, Type I curve is 
noted in 40%, Type II in 20%, and Type III in 40%.(Table 5 & figure 4). 
Sensitivity of evaluation of breast masses with BIRADS III  and 
above categories by Dynamic MR Mammogram curve patterns is 89.5% 
(95 CI 75.67%_ 100%), and the specificity is 96.2% (95 CI 88.76%_ 
100%) with Final Diagnosis by HPE as the gold standard.  
With MR Mammogram, the sensitivity and specificity were 
ranging from 80% to 98% in studies by Liu PF et al [49] and Mahfouz 
AE et al  [50] which is comparable to our study. 
Delille JP et al and Dean KI et al [51,52] assessed the degree of 
changes in parenchymal enhancement in relation to patient’s menstrual 
cycle. Study by Marklund M et al [53] assessed the effects of factors such 
as age,  intake of hormone replacement therapy and oral contraceptives. 
The hormonal effects on contrast enhancement is not assessed in our 
study. 
Positive predictive value of evaluation of breast masses with 
Dynamic MRI Mammogram curve categories is 94.4% (95 CI 83.86%_ 
100%) and the negative predictive value is 92.6% (95 CI 82.71%_ 
100%). 
Among the study group, 17 cases (89.47%) with histologically 
proven malignant breast masses were diagnosed as malignant with MRI 
type III curve and 25cases (96.15%) with benign breast masses were also 
correctly interpreted with MR Mammogram. 
False positive rate of evaluation of breast masses with Dynamic 
MRI Mammogram curve categories is 3.8% (95 CI 1.00%_ 11.2%) and 
the False negative rate is 10.5%(95 CI 1.00%-24.3%) with Final 
Diagnosis by HPE as the gold standard.  
Only false positive case with MR Mammogram in our study is a 
case of multiple fibrodenomas in inflammatory background, in which all 
lesions had type III curve enhancement pattern. 
Two false negative cases with MR Mammogram are two cases of 
ductal carcinoma in situ, in which tiny lesions had type II curve 
(intermediate) enhancement. 
The diagnostic accuracy of evaluation of breast masses of BIRADS 
III and above categories with Dynamic MRI Mammogram curve patterns 
is 93.3% (95 CI 86.05%_ 100%). (table 10) 
The comparision between Final Diagnosis of breast masses with 
HPE and Dynamic MR Mammogram curve analysis is statistically 
significant (P value <0.001). (Table 9) 
In Sonoelastography Grading, the incidence of Grade-2 score is 
26.67%, Grade-3 is 40%, Grade 4 is 26.67% and Grade -5 is 6.67% of the 
study population.(Table 6 & figure 5) 
Among the BIRADS categories, BIRADS III is noted in 48.89%, 
IV in 35.56%, V in 13.33% and VI in 2.22%.  (Table 7& figure 6) 
Sensitivity of Sonoelastography Grading in evaluation of breast 
masses with BIRADS III and above categories is 68.4% (95 CI 47.52%_ 
89.3%) and the specificity is 92.3% (95 CI 82.06%_ 100%). 
Positive predictive value of Sonoelastography in evaluation of 
breast masses with BIRADS III and above categories is 86.7% (95 CI 
69.46%_ 100%) and the Negative predictive value is 80% (95 CI 
65.69%_ 94.3%).   
Among our study group, 13(68.42%) cases of histopathologically 
proven malignancies were correctly diagnosed as malignant with 
Sonoelastography Grades 4 and 5.   24(92.31%) cases of benign breast 
masses were correctly diagnosed with Sonoelastography Grades 2 and 3 
as benign.    
False positive rate of Sonoelastography in evaluation of breast 
masses with BIRADS III and above categories is 7.7% (95 CI 1.00%_ 
17.9%) and the False negative rate is 31.6% (95 CI 10.68%_ 52.5%). 
The male case presented with palpable nodule under the nipple. On B 
mode USG, BIRADS IV lesion seen, which had grade 4elastographic 
score. On Dynamic MR Mammogram, type I curve (benign) was 
obtained. The male breast mass was finally proven to be a case of nodular 
gynecomastia (benign). 
2 cases (7.69%) with benign breast masses (one female with giant 
fibroadenoma and one male with nodular gynecomastia) were 
misdiagnosed as malignant by Sonoelastography. Presence of fibrotic 
components and undetected calcification on B mode USG are the 
potential causes of false positive Sonoelastography 
The overall diagnostic accuracy of Sonoelastography in evaluation 
of breast masses with BIRADS III and above categories is 82.2% (95 CI 
71.05%_93.4%). (Table 12) 
The comparision of the Final Diagnosis between HPE and 
Sonoelastography Grades is statistically significant (P value <0.001). 
(Table 11) 
 Similar to the study by Itoh et al [23] on sonoelastography, the 
score 1or 2 indicated by homogenous strain pattern suggestive of soft 
nature / benign lesions, is not found in any of our cases proved to be 
malignant. It helps to avoid unnecessary invasive histological evaluation 
of these lesions. 
In a study by Raza et al [54], 84% of malignant lesions were with 
elasticity scores 4 and 5. In our study 68.4% malignant masses were with 
elasticity scores 4 or 5 and  92.3% benign lesions had elasticity scores of 
2  and 3.  
In studies by Thomas A et al and Lee JH et al [55,56], the 
sensitivity of sonoelastography were ranging from 67% to 83%   and 
specificity from 86.7% to 90%. Studies by suggested that addition of 
elastographic findings to conventional B mode USG can improve the 
sensitivity and specificity.  
ElSaid NAet al [57] comparative study on sonoelastogram vs 
dynamic MR Mammogram on BIRADS III and above categories lesions 
had sensitivity of 84% for Sonoelastography and 88 % for MR 
Mammogram. The study had specificity of 84% for Sonoelastography 
and 80 % for MR Mammogram. 
Compared to previous studies [55,56,57], the specificity of 
Sonoelastography in diagnosing malignant breast masses is high in our 
study. 
Sonoelastography is cheaper compared to MRI, but it is highly 
operator dependant. 
Advantages of MR Mammogram includes its efficacy in evaluating 
the masses in dense breasts, has high image resolution, aids in evaluating 
the inverted nipples and is an noninvasive modality of imaging the ductal 
pathologies with an added advantage of imaging both breasts 
simultaneously. MR imaging is the choice of study in evaluation of 
augmented breasts with implants in situ.  
Limitations of MR Mammogram are it is more expensive 
compared to Ultrasound and it is not good at detecting calcifications. 
Periovulatory hormonal changes have an influence over the contrast 
enhancement patterns in MR Mammogram. 
  
 CONCLUSION 
Both sonoelastogram and MR mammogram are effective in 
characterising the malignant nature of the breast masses. Addition of 
elastography to conventional B mode USG aids in improved detection of 
breast masses.MRI is advantageous over Ultrasound in simultaneous 
diagnosis of multiple lesions in both breasts. Dynamic contrast MRI has 
an added advantage of early evaluation of in situ malignancies. 
Combination of both morphological and kinetic curve analysis has 
improved sensitivity and specificity of MR Mammogram. 
Both Sonoelastography and MR Mammogram are efficient 
techniques to evaluate breast lesions and can potentially decrease the 
number of unnecessary biopsies. 
In our study, both the sensitivity and specificity are high for MR 
Mammogram compared to Sonoelastography. 
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 PATIENT CONSENT FORM 
 
STUDY DETAIL : A comparative study on predictive value of 
malignancy in suspicious breast masses of BIRADS III & above 
categories using Sonoelastography and Dynamic MR Mammogram 
 
PATIENT’S NAME       :  
PATIENT’S AGE   : 
IDENTIFICATION NUMBER : 
 
I confirm that I have understood the purpose and procedure of the above 
study.  
I will be subjected to Sonoelastography and MR Mammmogram with 
contrast administration. I have the opportunity to ask questions and all my 
questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. 
However I understand that my identity would not be revealed in any 
information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
arise from this study. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical and followed by 
radiological tests . 
 
 
Patient’s signature/thumb impression: 
Patient’s name and address:                                              
Place:                              Date: 
 
 
Signature of the investigator:  Name of the investigator:                                                  
 
Place:                              Date: 
  
  
 
 
 
 
 
  
  
PROFORMA 
NAME: 
AGE: 
SEX: 
ADDRESS & PHONE NO: 
EDUCATION: 
GENERAL I.Q: 
OCCUPATION TYPE – PROFESSIONAL / SEMI SKILLED / 
UNSKILLED (MANUAL WORKER) 
MONTHLY INCOME: 
PRESENTING COMPLAINTS: 
 
 
HISTORY OF PREVIOUS SURGERIES: 
 
HISTORY OF ANY MEDICATIONS: 
 
MENSTRUAL AND OBSTETRIC HISTORY: 
 
GENERAL EXAMINATION:                                     
 
LOCAL  EXAMINATION : 
 
INSPECTION 
 
PALPATION 
 
B-MODE USG FINDINGS AND BIRADS: 
SONOELASTOGRAPHY SCORING: 
MRI MAMMOGRAM FINDINGS: 
 
DYNAMIC CONTRAST MRI MAMMOGRAM CURVE TYPE: 
PATIENT’S INFORMATION SHEET  
Magnetic resonance imaging (MRI) is a medical imaging technique used 
in radiology to image the anatomy and the physiological processes of the body 
in both health and disease.MRI scanners use strong magnetic fields, radio 
waves, and field gradients to form images of our body. 
During the scan, you lie on a table that slides inside a tunnel-shaped machine. 
Doing the scan can take a long time from 30 minutes to 60 minutes. The scan is 
painless. The MRI machine makes a lot of noise.  
The powerful magnetic field of the scanner can attract certain metallic objects 
known as ‘’ferromagnetic’’ objects, causing them to move suddenly and with 
great force towards the center of the MR system. Therefore, great care is taken 
to prevent Ferromagnetic objects from entering the MR system room. It is vital 
tom remove metallic objects in advance of an MRI exam, including watches, 
jewellery, and items of clothing that have metallic threads or fasteners. 
 A contrast agent called ‘’gadolinium’’ may be injected into a vein to help 
obtain a clearer picture of the area being examined. This is typically done 
through a small needle connected to an intravenous line that is placed in arm or 
hand vein. MRI contrast agents do not contain iodine and therefore, rarely 
cause allergic reactions or other problems.  
MRI Mammogram is done to characterise the breast lesion in detail. It has nil 
hazards. MRI Mammogram is of great value in breast masses characterisation.  
Sonoelastography is a new technique of ultrasound detecting the elasticity of 
tissues. Since it is use of ultrasound waves, has no ionization hazards. It is less 
time consuming. It is noninvasive.      
You will be first subjected to sonoelastogram and MR Mammogram to 
characterise your breast pathology and  followed by FNAC / Biopsy 
correlation. 
  
  
ABBREVIATIONS 
1. BI-RADS- Breast Imaging-Reporting and Data System 
2. USG-ultrasonography 
3. MRI- magnetic resonance imaging 
4. TDLU- Terminal ductal lobular unit 
5. TNBC- triple-negative breast carcinoma 
6. BMI- body mass index 
7. ARFI- acoustic radiation force impulse 
8. RSV-Real-time shear velocity 
9. AUC- Area under the curve 
10. DCIS-Ductal carcinoma in situ 
11. LCIS-Lobular carcinoma in situ 
12. HMW-high molecular weight 
13. ILC-Invasive lobular carcinoma 
14. IDC-Invasive Ductal carcinoma 
15. IBC-Inflammatory Breast Cancer 
16. FNAC- Fine Needle aspiration biopsy 
17. VABB -Vacuum-assisted breast biopsy 
18. STIR- short tau inversion recovery 
19. HPE-Histopathological examination 
20. CI-Confidence IntervaI 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
S. NO 
MRI 
ID 
NO. NAME 
AGE 
/SEX RIGHT/LEFT 
MRI 
CURVE 
USG 
ELASTOGRAM 
GRADE BIRADS HPE 
BENIGN =1, 
MALIGNANT = 2 
1 1707 SANDHIYA 21/F BOTH TYPE III 2 &3 IV 
FIBROADENOMAS IN 
INFLAMMATORY 
BACKGROUND 1 
2 1341 AMALA 29/F RIGHT TYPE  II 2 III MASTITIS 1 
3 3375 
AMUDHA  
RAMESH 40/F LEFT TYPE I 2 IV GRANULOMA 1 
4 2145 ANJALATCHI 58/F LEFT TYPE II 3 III DCIS 2 
5 2567 BHAVANI 37/F RIGHT TYPE III 4 V MEDULLARY CA 2 
6 2159 DEVAGI 74/F LEFT TYPE III 4 VI INVASIVE DUCTAL CA 2 
7 3574 SORNAM 56/F BOTH TYPE I 3 III FIBROADENOMA 1 
8 1631 SRIDEVI 40/F RIGHT TYPE I 2 III FIBROADENOMA 1 
9 2208 IDAYATHISHA 65/F LEFT TYPE III 5 V INVASIVE DUCTAL CA 2 
10 90 JAYASHREE 40/F LEFT TYPE II 3 III FIBROADENOMA 1 
11 265 KANAGAVALLI 55/F RIGHT TYPE III 4 IV DCIS 2 
12 3451 KASIAMMAL 55/F LEFT TYPE III 4 V INVASIVE LOBULAR  CA 2 
13 3313 MOHANA 40/F LEFT TYPE I 2 III DUCT ECTASIA 1 
14 2446 PARVATHY 48/F RIGHT TYPE I 3 III GRANULOMA 1 
15 1756 PUNITHAVALLI 46/F BOTH TYPE II 2 III FIBROADENOMA 1 
16 1847 RANI 50/F LEFT TYPE III 3 IV DCIS 2 
17 254 SANDHYA 22/F BOTH TYPE II 3 III MULTIPLE FIBROADENOMAS 1 
18 2129 SANGEETHA 37/F BOTH TYPE I 2 III FIBROADENOMAS 1 
19 1220 SHANTHI 45/F RIGHT TYPE III 4 IV DCIS 2 
20 3178 SUNIL KUMAR 21/M LEFT TYPE I 4 IV NODULAR GYNAECOMASTIA 1 
21 3626 TAMILARASI 40/F BOTH TYPE I 3 III HEMORRHAGIC CYST 1 
22 2179 THULASIMALA 55/F LEFT TYPE I 3 IV FIBROADENOMA 1 
23 1035 VANITHA 44/F RIGHT TYPE I 3 III FIBROADENOMA 1 
24 3172 VIMALA 32/F LEFT TYPE I 2 III MASTITIS 1 
25 1399 NISHANTHI 26 F RIGHT TYPE I 2 III FIBROADENOSIS 1 
26 1437 GAYATHRI 31 F RIGHT TYPE I 3 III DUCT ECTASIA 1 
27 940 MARIA 40 F LEFT TYPE II 2 III FIBROADENOMA 1 
28 1033 CHITRA 37 F LEFT TYPE II 3 IV DCIS 2 
29 3111 REVATHY 28F LEFT TYPE II 3 IV PHYLLOIDES 1 
30 586 SUGITHA 32F RIGHT TYPE III 5 V INVASIVE DUCTAL CA 2 
31 1033 CHITRA 37 F RIGHT TYPE II 3 III DUCT ECTASIA 1 
32 999 PAVALAM 41F RIGHT TYPE I 2 III FIBROADENOMA 1 
33 1102 MARY 54F LEFT TYPE I 2 III PHYLLOIDES 1 
34 80 JANAKI 33F RIGHT TYPE I 4 IV GIANT FIBROADENOMA 1 
35 564 VINIYHA 32F LEFT TYPE III 3 IV DCIS 2 
36 654 VIDHYA 52F RIGHT TYPE III 4 III INFLAMATORY CA 2 
37 323 BEGUM 25F RIGHT TYPE III 4 IV INVASIVE DUCTAL CA 2 
38 213 GHEETHA 27F LEFT TYPE III 3 III DCIS 2 
39 1103 JANAKI 33F RIGHT TYPE III 4 IV INVASIVE LOBULAR CA 2 
40 231 ANNALAKSHMI 44F RIGHT TYPE I 3 III GIANT FIBROADENOMA 1 
41 956 CHITRA 35F LEFT TYPE III 3 IV DCIS 2 
42 556 NITHYA 36F RIGHT TYPE III 4 V INFLAMATORY CA 2 
43 456 HEMA 29F RIGHT TYPE III 4 IV INVASIVE DUCTAL CA 2 
44 133 SENTHAMARAI 32F LEFT TYPE III 5 V MUCINOUS CA 2 
45 651 KALAVATHY 33F LEFT TYPE I 2 IV DUCTAL PAPILLOMA 1 
 
